Posted On: 19 May 2022
MAKING HEADLINES
Herald Sun Reporter, Owen Leonard, met with Botanix executives while they were in Australia this week and has published a story about the Company’s recent acquisition of Sofpironium Bromide.
This novel potential treatment for primary axillary hyperhidrosis, a medical condition that results in excessive underarm sweat, is bringing new hope for sufferers.
Botanix Executive Director, Matthew Callahan, explained why it could fill a market gap:
“At the moment, to treat it, you’ve got a couple of options. You’ve got antiperspirants – covers up the smell but does nothing to actually have an effect on the excessive sweating – and at the other extreme, you’ve got surgery, where they’ll actually go in and cut the nerve to stop the signals getting to the sweat gland to stop you sweating excessively.
“In between, there’s been a lot of drugs that have been around for decades that don’t work very well and have all sorts of nasty side effects.”